文献速递炎症性肠病

生物制剂治疗合并内瘘的克罗恩病的长期结局:GETECCU 的 BIOSCOPE 研究

Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU.
PubMed 文献 · Am J Gastroenterol · 2022-12-14

基于 ENEIDA 前瞻性登记数据库,纳入 760 例接受至少一种生物制剂治疗的合并内瘘克罗恩病患者,中位随访 56 个月。240 例需瘘相关手术,抗肿瘤坏死因子、维得利珠单抗、乌司奴单抗组手术率分别为 32%、41%、24%,24% 患者实现瘘管闭合。

要点

  • 合并内瘘的克罗恩病患者接受生物制剂后约四分之三可获益,24% 实现瘘管闭合。
  • 抗肿瘤坏死因子、维得利珠单抗、乌司奴单抗组手术率分别为 32%、41%、24%。
  • 年长、回结肠病变、肠泌尿瘘或瘘口远端肠狭窄与手术风险升高相关,非吸烟及联合免疫调节剂降低风险。

核心结论

  • 生物制剂治疗对约四分之三的合并内瘘克罗恩病患者有益,24% 实现瘘管闭合,但约三分之一仍因难治性疾病接受手术。
  • 部分患者及病变相关因素可识别从这些药物中获得更多益处的患者。

研究设计与样本

  • 基于前瞻性维护的 ENEIDA 登记数据库,纳入接受至少 1 种生物制剂治疗的克罗恩病相关内瘘成人患者。
  • 排除因肛周病变、肠皮瘘、直肠阴道瘘、吻合口瘘或造口旁瘘接受生物制剂者。
  • 共纳入来自 53 家医院的 760 例患者,其中 673 例接受抗肿瘤坏死因子、69 例接受乌司奴单抗、18 例接受维得利珠单抗。
  • 主要终点为瘘相关手术,采用多因素 logistic 回归和生存分析评估与手术及瘘管闭合相关的预测因素。

主要发现

  • 中位随访 56 个月(四分位距 26–102 个月)后,240 例患者需手术。
  • 抗肿瘤坏死因子、维得利珠单抗、乌司奴单抗组手术率分别为 32%、41%、24%。
  • 24% 患者观察到瘘管闭合。
  • 年长患者、回结肠病变、肠泌尿瘘或瘘口起源远端肠狭窄与手术风险升高相关,非吸烟及联合免疫调节剂治疗降低该风险。

关键数值与推荐

  • 主要终点为瘘相关手术。
  • 手术率:抗肿瘤坏死因子组 32%、维得利珠单抗组 41%、乌司奴单抗组 24%。
  • 瘘管闭合率 24%。
  • 与手术风险升高相关的因素:年长患者、回结肠病变、肠泌尿瘘、瘘口起源远端肠狭窄。
  • 与手术风险降低相关的因素:非吸烟、联合免疫调节剂治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The prevalence of penetrating complications in Crohn's disease (CD) increases progressively over time, but evidence on the medical treatment in this setting is limited. The aim of this study was to evaluate the effectiveness of biologic agents in CD complicated with internal fistulizing disease. METHODS: Adult patients with CD-related fistulae who received at least 1 biologic agent for this condition from the prospectively maintained ENEIDA registry were included. Exclusion criteria involved those receiving biologics for perianal disease, enterocutaneous, rectovaginal, anastomotic, or peristomal fistulae. The primary end point was fistula-related surgery. Predictive factors associated with surgery and fistula closure were evaluated by multivariate logistic regression and survival analyses. RESULTS: A total of 760 patients from 53 hospitals (673 receiving anti-tumor necrosis factors, 69 ustekinumab, and 18 vedolizumab) were included. After a median follow-up of 56 months (interquartile range, 26-102 months), 240 patients required surgery, with surgery rates of 32%, 41%, and 24% among those under anti-tumor necrosis factor, vedolizumab, or ustekinumab, respectively. Fistula closure was observed in 24% of patients. Older patients, ileocolonic disease, entero-urinary fistulae, or an intestinal stricture distal to the origin of the fistula were associated with a higher risk of surgery, whereas nonsmokers and combination therapy with an immunomodulator reduced this risk. DISCUSSION: Biologic therapy is beneficial in approximately three-quarters of patients with fistulizing CD, achieving fistula closure in 24%. However, around one-third still undergo surgery due to refractory disease. Some patient- and lesion-related factors can identify patients who will obtain more benefit from these drugs.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Barreiro-de Acosta M, Fernández-Clotet A, Mesonero F, et al. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU. Am J Gastroenterol. 2022. PMID: 36516073. doi:10.14309/ajg.0000000000002152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。